GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2021-09-24| China

China Drugmaker Aims for First Generic Drug Approval of Novartis’ Tasigna in China

by Tyler Chen
Share To
Photo/ Suzhou Therypharm Pharmaceutical

Suzhou Therypharm Pharmaceutical’s filing for approval of its generic blood cancer drug in China has been accepted by the country’s CDE (Center for Drug Evaluation). This is a game-changer for generic versions of Novartis’ Tasigna (nilotinib); so far, the oral pill faces zero competition in the generic market. With the CDE acceptance of its filing, Therypharm takes the lead in the category and could possibly be the first company that produces nilotinib’s generic version in China.

 

Tap Into a Near $2 Billion Market

Nilotinib is a small-molecule tyrosine kinase inhibitor that targets the BCR-ABL protein. It is approved to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults and children who are at least 1 year old.

There is huge market demand for the drug. Novartis’s report ranks nilotinib in 4th place on net sales of their top 20 innovative medicines division product, bringing in $1.93 billion in 2020. In the first half of 2021 alone, nilotinib sales hit $1.038 billion with $523 million from Q2.

Besides nilotinib, Therypharm also worked on other generics, including for Astellas and Roche’s lung cancer drug Tarceva, AstraZeneca’s cancer drug Iressa, and cardiovascular disease drug Ticagrelor. Those were approved in China in 2021.

 

Therypharm’s Series C Round

In September 2020, the firm finished a Series C round with $38 million in hand. The funding was led by state-backed SND Ventures Group and investment firm CEC Capital. Other investors included GP Capital’s Su Shang Fund, Suzhou International Development Venture Capital Holding’s sub-fund, Honest Capital, and Taiho Venture Capital.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Pharma’s Growing (R)evolution: Sustainability and Innovations Shaping the Industry
2025-01-07
Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals
2024-09-18
Novartis Achieves 11% Sales Growth with Strong Performance in Heart Failure, Immune Drugs, and R&D in Q2
2024-08-06
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top